Bicara Therapeutics (NASDAQ: BCAX) details Phase 3 dose, 2026 outlook

Rhea-AI Filing Summary

Bicara Therapeutics Inc. filed a Form 8-K to report that it issued a press release on January 12, 2026 titled “Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook.”

The company states that this press release is furnished as Exhibit 99.1 and incorporated by reference, indicating it contains details on the chosen Phase 3 dose and management’s outlook for 2026.

FALSE000202365800020236582026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): January 12, 2026

___________________________________

Bicara Therapeutics Inc.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware (State or other jurisdiction of incorporation or organization)			001-42271 (Commission File Number)			83-2903745 (I.R.S. Employer Identification Number)
116 Huntington Avenue, Suite 703 Boston, MA 02116
(Address of principal executive offices and zip code)
(617) 468-4219
(Registrant's telephone number, including area code)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class			Trading Symbol			Name of each exchange on which registered
Common Stock, $0.0001 par value			BCAX			The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company    ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 8.01 - Other Events.

On January 12, 2026, Bicara Therapeutics Inc. issued a press release entitled “Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 - Financial Statements and Exhibits

(d) The following exhibits are being filed herewith:

Exhibit No.						Description
99.1						Press Release, dated January 12, 2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 12th day of January 12, 2026.

Bicara Therapeutics Inc.
By:			/s/ Claire Mazumdar
Name:			Claire Mazumdar, Ph.D.
Title:			Chief Executive Officer

FAQ

What did Bicara Therapeutics (BCAX) report in this Form 8-K?

Bicara Therapeutics reported that it issued a press release titled “Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook.”

When did Bicara Therapeutics issue the Phase 3 dose and 2026 outlook press release?

The press release was issued on January 12, 2026.

How is the Bicara Therapeutics press release made available to investors?

The press release is attached as Exhibit 99.1 to the Form 8-K and is incorporated by reference.

What topics are covered in Bicara Therapeutics’ January 12, 2026 press release?

According to the title, the press release covers the Phase 3 optimal dose and provides a 2026 corporate outlook.

Which exchange is Bicara Therapeutics’ common stock listed on?

Bicara Therapeutics’ common stock is listed on The Nasdaq Global Market under the symbol BCAX.

Who signed the Form 8-K for Bicara Therapeutics?

The Form 8-K was signed on behalf of Bicara Therapeutics Inc. by Claire Mazumdar, Ph.D., Chief Executive Officer.